Hormone therapy and the risk of stroke: Perspectives 10 years after the Women's Health Initiative trials

Climacteric

Volumn 15, Issue 3, 2012, Pages 229-234

  Henderson, V W ^a   Lobo, R A ^b  

^a STANFORD UNIVERSITY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

ESTROGEN; HORMONE THERAPY; PROGESTOGEN; RALOXIFENE; REVIEW; STROKE; TAMOXIFEN; TIBOLONE; WOMEN'S HEALTH INITIATIVE

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; RALOXIFENE; TAMOXIFEN; TIBOLONE;

AGING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DISEASE ASSOCIATION; FEMALE; HORMONAL THERAPY; HUMAN; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; WOMEN'S HEALTH;

AGE FACTORS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; TIME FACTORS; WOMEN'S HEALTH;

EID: 84861412574     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.656254     Document Type: Review

References (39)

1. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009;8:355-69
2. Lethbridge-Çejku M, Vickerie J. Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2003. Vital and Health Statistics 2005;10(225)
3. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 2011;124: 314-23
4. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376: 112-23
5. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003;2:43-53 (Pubitemid 37443343)
6. Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA. Gender differences in stroke incidence and poststroke disability in the Framingham heart study. Stroke 2009;40: 1032-7
7. Lisabeth LD, Beiser AS, Brown DL, Murabito JM, Kelly-Hayes M, Wolf PA. Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke 2009;40:1044-9
8. Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischemic stroke. Menopause 2011 Oct 6. Epub ahead of print
9. Mohr JP, Caplan LR, Melski JW, et al . The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978;23: 754-62 (Pubitemid 8382975)
10. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis 2009;27:493-501
11. Ruiz VC, Soler EP. Epidemiology and risk factors of cerebral ischemia and ischemic heart disease: similarities and differences. Curr Cardiol Rev 2010;6:138-49
12. Paganini-Hill A. Hormone replacement therapy and stroke: risk, protection or no effect? Maturitas 2002;38:243-61
13. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37
14. Simon JA, Hsia J, Cauley JA, et al . Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen/progestin Replacement Study (HERS). Circulation 2001;103:638-42 (Pubitemid 32144190)
15. Henderson VW. Alzheimer's disease and other neurological disorders. Climacteric 2007;10(Suppl 2):92-6 (Pubitemid 47450843)
16. Viscoli CM, Brass LM, Kernan WN, Sarrel SM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9 (Pubitemid 34951488)
17. Women's Health Initiative Study Group. Design of the Women'sHealth Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109
18. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33 (Pubitemid 34761611)
19. Anderson GL, Limacher M, Assaf AR, et al . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12 (Pubitemid 38489892)
20. Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289:2673-84 (Pubitemid 37430138)
21. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425-34 (Pubitemid 43948050)
22. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77 (Pubitemid 46556472)
23. Coker LH, Hogan PE, Bryan NR, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMSMRI Study. Neurology 2009;72:125-34
24. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45 (Pubitemid 351347060)
25. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14
26. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330:342
27. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-6 (Pubitemid 351620088)
28. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
29. Umetani M, Domoto H, Gormley AK, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 2007;13:1185-92 (Pubitemid 47530633)
30. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007;14:373-84
31. Lobo RA, Clarkson TB. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause 2011; 18:237-40
32. Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011;18:1052-9
33. Barrett-Connor E, Grady D, Sashegyi A, et al . Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287: 847-57 (Pubitemid 34252031)
34. Barrett-Connor E, Mosca L, Collins P, et al . Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37 (Pubitemid 44050394)
35. Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D. Raloxifene and risk for stroke based on the Framingham stroke risk score. Am J Med 2009;122:754-61
36. Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 2004;63:1230-3 (Pubitemid 39350022)
37. Cummings SR, Ettinger B, Delmas PD, et al . The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359: 697-708
38. Renoux C, Dell'aniello S, Garbe E, Suissa S. Hormone therapy use and the risk of stroke. Maturitas 2008;61:305-9
39. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(Suppl 1):s1-66